Alvotech opens state-of-the-art biosimilar facility in Iceland
The new facility will significantly increase Alvotech’s production capacity enabling the group to produce higher yields at lower costs.
Alvotech, an independent sister company of Alvogen, has opened a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (mAbs). The opening of this biologics manufacturing plant marks a significant milestone for both Alvogen and Alvotech.
Through the Alvotech-Alvogen alliance, Alvogen directly benefits from the growth of Alvotech due the increased supply of products coming to market. Alvotech currently runs five offices in Iceland, Germany, Switzerland and Malta, which in turn helps Alvogen to maximise its distribution of the products. Alvogen is already advanced in the distribution of biosimilars through its relationship with Hospira/Pfizer and it currently distributes products in 35 countries with a target revenue generation of $3 billion by 2020.
Alvotech has worked with the FDA and European EMA regulatory agencies to design and build a facility complying with the highest quality standards. The 13,000 m2 facility is located the science park of the University of Iceland in Reykjavik. Iceland offers a favourable operating environment with a strong regulatory system and a convenient geographical location. Furthermore the new facility will significantly increase Alvotech’s production capacity enabling the group to produce higher yields at lower costs.
Robert Wessman, Chairman and CEO of Alvogen said: “The relationship we have with Alvotech continues to form a central component of our own growth strategy as we continue to expand our global network. The opening of this new facility, helps us to establish ourselves as leaders in the biopharmaceutical industry. Our focus is on our patients and, with this new state-of-the-art manufacturing facility, combined with our commercial network, we are able to continue to deliver high quality products to our customers.”
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance